•
Jun 30, 2023

ResMed Q4 2023 Earnings Report

ResMed's Q4 2023 earnings showcased strong double-digit growth, driven by increased demand for sleep and respiratory care devices and software solutions.

Key Takeaways

ResMed Inc. reported a 23% increase in revenue to $1.1 billion for the fourth quarter of fiscal year 2023. Diluted earnings per share were $1.56, and non-GAAP diluted earnings per share were $1.60. The company's performance was driven by strong global demand for its cloud-connected flow generator devices, patient interfaces, and software solutions.

Revenue increased by 23% to $1.1 billion, reflecting strong growth in constant currency.

Diluted earnings per share (EPS) reached $1.56, while non-GAAP diluted EPS was $1.60.

Operating cash flow was $237.4 million for the quarter.

The company's software-as-a-service revenue increased by 34%.

Total Revenue
$1.12B
Previous year: $915M
+22.7%
EPS
$1.6
Previous year: $1.49
+7.4%
Gross Profit
$617M
Previous year: $523M
+18.2%
Cash and Equivalents
$228M
Previous year: $274M
-16.7%
Free Cash Flow
$203M
Previous year: $50.8M
+299.2%
Total Assets
$6.75B
Previous year: $5.1B
+32.5%

ResMed

ResMed

ResMed Revenue by Segment

ResMed Revenue by Geographic Location

Forward Guidance

ResMed is focused on delivering therapy and digital health solutions to improve people's lives outside the hospital, aiming to help 250 million lives in 2025.